CAR-T and other adoptive cell therapies for B cell malignancies
B cell malignancies pose challenges due to therapeutic resistance and repeated relapse. Advances in adoptive cellular therapies including chimeric antigen receptor (CAR)-T cells have the potential to transform the treatment landscape in hematological and solid tumor cancers. Improvements in construc...
Guardado en:
Autores principales: | Peihua Lu, Holly A. Hill, Lucy J. Navsaria, Michael L. Wang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/13baf7e057a4433f9f07fc68916d37eb |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VIII: CAR-T cells: preclinical development - Safety and efficacy evaluation
por: Virginia Picanço-Castro, et al.
Publicado: (2021) -
Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors
por: Christopher Sloas, et al.
Publicado: (2021) -
Adoptive chimeric antigen receptor T cell (CAR-T) and Treg cell-based immunotherapies: Frontier therapeutic aspects in cancers
por: Mehran Bahraini, et al.
Publicado: (2021) -
Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells
por: Cristina Aparicio, et al.
Publicado: (2021) -
How Can We Engineer CAR T Cells to Overcome Resistance?
por: Glover M, et al.
Publicado: (2021)